Education
About Us
Working with TipRanks
Follow Us
Alembic Pharmaceuticals Limited (IN:APLLTD)
:APLLTD
Total Valuation
Alembic Pharmaceuticals Limited has a market cap or net worth of ₹184.90B. The enterprise value is ₹111.44B.
Market Cap₹184.90B
Enterprise Value₹111.44B
Share Statistics
Alembic Pharmaceuticals Limited has 196,563,130 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding196,563,130
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Alembic Pharmaceuticals Limited’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is 41.53%.
Return on Equity (ROE)0.11
Return on Assets (ROA)0.08
Return on Invested Capital (ROIC)41.53%
Return on Capital Employed (ROCE)0.62
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover0.86
Inventory Turnover0.78
Valuation Ratios
The current PE Ratio of Alembic Pharmaceuticals Limited is 30.22. Alembic Pharmaceuticals Limited’s PEG ratio is 0.40.
PE Ratio30.22
PS Ratio0.00
PB Ratio4.12
Price to Fair Value3.40
Price to FCF41.69
Price to Operating Cash Flow24.69
PEG Ratio0.40
Income Statement
In the last 12 months, Alembic Pharmaceuticals Limited had revenue of 66.72B and earned 5.83B in profits. Earnings per share was 29.68.
Revenue66.72B
Gross Profit48.79B
Operating Income33.16B
Pretax Income7.07B
Net Income5.83B
EBITDA10.08B
Earnings Per Share (EPS)29.68
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Alembic Pharmaceuticals Limited pays an annual dividend of ₹11, resulting in a dividend yield of 1.17%
Dividend Per Share₹11
Dividend Yield1.17%
Payout Ratio37.93%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.89
52-Week Price Change5.44%
50-Day Moving Average929.22
200-Day Moving Average998.45
Relative Strength Index (RSI)44.43
Average Volume (3m)10.19K
Important Dates
Alembic Pharmaceuticals Limited upcoming earnings date is Jul 29, 2025, TBA Not Confirmed.
Last Earnings DateMay 6, 2025
Next Earnings DateJul 29, 2025
Ex-Dividend DateJul 29, 2025
Financial Position
Alembic Pharmaceuticals Limited as a current ratio of 1.69, with Debt / Equity ratio of 10.65%
Current Ratio1.69
Quick Ratio0.75
Debt to Market Cap0.07
Net Debt to EBITDA1.16
Interest Coverage Ratio42.10
Taxes
In the past 12 months, Alembic Pharmaceuticals Limited has paid 1.25B in taxes.
Income Tax1.25B
Effective Tax Rate0.18
Enterprise Valuation
Alembic Pharmaceuticals Limited EV to EBITDA ratio is 18.64, with an EV/FCF ratio of -39.52.
EV to Sales2.82
EV to EBITDA18.64
EV to Free Cash Flow-39.52
EV to Operating Cash Flow213.67
Balance Sheet
Alembic Pharmaceuticals Limited has ₹901.00M in cash and marketable securities with ₹12.57B in debt, giving a net cash position of ₹11.67B billion.
Cash & Marketable Securities₹901.00M
Total Debt₹12.57B
Net Cash₹11.67B
Net Cash Per Share₹59.39
Tangible Book Value Per Share₹264.00
Margins
Gross margin is 36.43%, with operating margin of 49.71%, and net profit margin of 8.74%.
Gross Margin36.43%
Operating Margin49.71%
Pretax Margin10.60%
Net Profit Margin8.74%
EBITDA Margin15.11%
EBIT Margin10.94%
Analyst Forecast
The average price target for Alembic Pharmaceuticals Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―